Go Pro
→ If you keep cash in a U.S. bank account… read this NOW (From Banyan Hill Publishing) (Ad)tc pixel Free NEUP Stock Alerts

Neuphoria Therapeutics (NEUP) Financials

Neuphoria Therapeutics logo
$3.68 -0.05 (-1.34%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$3.68 -0.01 (-0.14%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Neuphoria Therapeutics

Annual Income Statements for Neuphoria Therapeutics

This table shows Neuphoria Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025 2026
Period end date 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -4.02 -6.53 -15 -22 -15 -0.37 -13
Consolidated Net Income / (Loss)		 -4.92 -6.53 -15 -21 -15 -0.37 -13
Net Income / (Loss) Continuing Operations		 -4.02 -6.53 -15 -21 -15 -0.37 -13
Total Pre-Tax Income 		-4.17 -6.67 -15 -22 -16 -0.84 -14
Total Operating Income		 -9.62 -11 -19 -22 -18 -1.13 -16
Total Gross Profit		 -2.24 -2.29 0.19 0.00 0.00 16 1.17
Total Revenue		 0.03 0.00 0.19 0.00 0.00 16 1.17
Operating Revenue		 0.03 0.00 0.19 - 0.00 16 1.17
Total Cost of Revenue		 2.27 2.30 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 7.38 8.57 19 22 18 17 18
Selling, General & Admin Expense		 2.54 3.29 5.11 8.91 8.47 7.77 7.44
Research & Development Expense		 4.03 4.33 11 13 9.42 9.01 3.55
Impairment Charge		 - - - - - 0.00 5.36
Restructuring Charge		 - - - - - 0.00 1.28
Total Other Income / (Expense), net		 5.45 4.19 3.60 0.32 2.31 0.29 2.86
Interest & Investment Income		 - - - 0.32 0.22 0.17 0.67
Other Income / (Expense), net		 5.45 4.19 3.60 - 2.09 0.12 2.19
Income Tax Expense		 -0.14 -0.14 -0.13 -0.14 -0.09 -0.47 -0.14
Basic Earnings per Share		 - - - ($0.02) ($18.62) ($0.23) ($3.06)
Weighted Average Basic Shares Outstanding		 - - 1.35B 1.47B 832.23K 1.62M 4.40M
Diluted Earnings per Share		 ($0.01) ($0.01) - - ($18.62) ($0.23) ($3.06)
Weighted Average Diluted Shares Outstanding		 - - 1.35B 1.49B 832.23K 1.62M 4.40M
Weighted Average Basic & Diluted Shares Outstanding		 - - 1.35B 1.49B - - 5.41M

Quarterly Income Statements for Neuphoria Therapeutics

This table shows Neuphoria Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q3 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2025 12/31/2024 3/31/2025 6/30/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -5.54 -4.55 -2.78 -2.62 -9.91 -1.94 11 -8.88 -0.51
Consolidated Net Income / (Loss)		 -5.47 -4.55 -2.78 -2.69 -9.91 -1.94 11 -8.88 -0.51
Net Income / (Loss) Continuing Operations		 -5.47 -4.55 -2.78 -2.69 -9.91 -1.94 11 -8.88 -0.51
Total Pre-Tax Income 		-5.51 -4.59 -2.76 -2.72 -9.94 -1.93 11 -9.15 -0.54
Total Operating Income		 -5.47 -4.55 -2.39 -5.48 -5.65 -3.70 12 -5.84 -1.21
Total Gross Profit		 0.00 0.00 0.00 - 0.00 0.66 15 -0.01 0.00
Total Revenue		 0.00 0.00 0.00 - 0.00 0.66 15 -0.01 0.00
Operating Revenue		 - 0.00 0.00 - 0.00 0.66 15 - 0.00
Total Cost of Revenue		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 5.47 4.55 2.39 5.48 5.65 4.37 3.02 5.82 1.21
Selling, General & Admin Expense		 2.38 2.52 1.20 2.38 1.87 2.63 1.41 2.07 1.69
Research & Development Expense		 3.09 2.03 1.20 3.10 3.79 1.74 1.62 3.75 -0.52
Restructuring Charge		 - - - - - 0.00 0.00 - 0.04
Total Other Income / (Expense), net		 -0.04 -0.04 -0.37 2.76 -4.29 1.77 -0.80 -3.32 0.67
Interest & Investment Income		 0.09 0.05 0.05 0.03 0.14 0.03 0.01 0.09 0.19
Other Income / (Expense), net		 -0.12 -0.09 -0.42 2.73 -4.43 1.74 -0.81 -3.40 0.49
Income Tax Expense		 -0.03 -0.03 0.02 -0.03 -0.03 0.01 -0.08 -0.27 -0.03
Basic Earnings per Share		 $0.00 ($5.31) ($2.83) ($10.48) ($4.41) ($1.23) $6.55 ($5.55) ($0.09)
Weighted Average Basic Shares Outstanding		 1.50B 857.26K 981.04K 832.23K 2.25M 1.58M 1.72M 1.62M 5.41M
Diluted Earnings per Share		 $0.00 ($5.31) ($2.83) ($10.48) ($4.41) ($1.79) $6.55 ($5.55) ($0.09)
Weighted Average Diluted Shares Outstanding		 1.50B 857.26K 981.04K 832.23K 2.25M 1.58M 1.72M 1.62M 5.41M
Weighted Average Basic & Diluted Shares Outstanding		 - - - 0.00 5.38M 5.39M 1.88M 0.00 5.40M

Annual Cash Flow Statements for Neuphoria Therapeutics

This table details how cash moves in and out of Neuphoria Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025 2026
Period end date 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025 6/30/2026
Net Change in Cash & Equivalents		 -6.54 18 7.99 -11 0.50 1.60 5.58
Net Cash From Operating Activities		 -2.70 -5.66 -15 -15 -15 0.08 -12
Net Cash From Continuing Operating Activities		 -0.92 -0.55 -15 -15 -15 0.08 -12
Net Income / (Loss) Continuing Operations		 0.00 0.00 0.00 -21 -15 -0.37 -13
Consolidated Net Income / (Loss)		 - - - -21 -15 -0.37 -13
Depreciation Expense		 - - - 0.66 0.66 0.66 0.66
Non-Cash Adjustments To Reconcile Net Income		 - - -15 0.90 0.56 -0.44 4.69
Changes in Operating Assets and Liabilities, net		 -0.92 -0.55 - 5.18 -0.41 0.22 -4.25
Net Cash From Investing Activities		 -0.13 -0.06 0.49 0.00 0.00 0.00 0.00
Net Cash From Continuing Investing Activities		 -0.13 -0.06 0.49 0.00 0.00 0.00 0.00
Net Cash From Financing Activities		 -3.70 24 23 3.86 15 1.53 18
Net Cash From Continuing Financing Activities		 -3.70 24 23 3.86 15 1.53 18
Issuance of Common Equity		 2.25 33 - 0.00 15 1.53 18
Other Financing Activities, net		 - - 23 3.86 0.00 0.00 0.00
Effect of Exchange Rate Changes		 - - - - 0.08 -0.00 0.01
Cash Interest Paid		 - - - 0.00 0.03 0.02 0.00
Cash Income Taxes Paid		 - - - 0.00 0.05 0.00 0.00

Quarterly Cash Flow Statements for Neuphoria Therapeutics

This table details how cash moves in and out of Neuphoria Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q4 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2025 12/31/2025 3/31/2025 6/30/2025 6/30/2026
Net Change in Cash & Equivalents		 -4.32 2.37 -1.73 4.18 -0.56 8.52 -3.53 -2.83 0.42
Net Cash From Operating Activities		 -4.43 -3.95 -3.30 -3.01 -3.79 -6.44 14 -3.59 1.21
Net Cash From Continuing Operating Activities		 -4.43 -3.95 -3.30 -3.01 -3.79 -6.44 14 -3.59 1.21
Net Income / (Loss) Continuing Operations		 -5.47 -4.55 -2.78 -2.69 -9.91 1.86 17 -8.88 -4.90
Consolidated Net Income / (Loss)		 -5.47 -4.55 -2.78 -2.69 -9.91 1.86 17 -8.88 -4.90
Depreciation Expense		 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17
Non-Cash Adjustments To Reconcile Net Income		 0.20 0.81 -0.15 -0.29 4.56 -4.97 -2.83 2.81 5.78
Changes in Operating Assets and Liabilities, net		 0.68 -0.36 -0.53 -0.20 1.38 -3.49 0.01 2.32 0.17
Effect of Exchange Rate Changes		 - - -0.19 0.07 -0.02 0.30 -0.33 0.05 -0.79

Annual Balance Sheets for Neuphoria Therapeutics

This table presents Neuphoria Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024 2025 2026
Period end date 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025 6/30/2026
Total Assets		 41 45 29 28 29 29
Total Current Assets		 23 29 13 13 15 21
Cash & Equivalents		 21 23 12 13 14 20
Restricted Cash		 - - - 0.00 0.08 0.00
Accounts Receivable		 0.15 0.04 0.43 0.13 0.01 0.81
Prepaid Expenses		 - - 0.80 0.46 0.74 0.39
Plant, Property, & Equipment, net		 0.01 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 18 16 15 14 14 7.64
Goodwill		 9.32 8.89 8.69 8.69 8.64 3.50
Intangible Assets		 7.47 6.79 6.13 5.47 4.80 4.14
Other Noncurrent Operating Assets		 0.74 0.54 0.41 0.30 0.10 0.00
Total Liabilities & Shareholders' Equity		 39 43 29 28 29 29
Total Liabilities		 5.01 5.80 6.55 10 9.59 4.11
Total Current Liabilities		 1.77 2.32 2.74 3.83 4.22 0.76
Accounts Payable		 1.36 1.92 1.44 2.24 1.15 0.39
Accrued Expenses		 - - 1.19 1.46 2.95 0.37
Other Current Liabilities		 0.41 0.39 0.11 0.12 0.12 0.00
Total Noncurrent Liabilities		 3.23 3.48 3.81 6.33 5.37 3.35
Capital Lease Obligations		 0.52 0.37 0.24 0.12 0.00 0.00
Noncurrent Deferred & Payable Income Tax Liabilities		 1.38 1.24 1.10 0.96 0.50 0.36
Other Noncurrent Operating Liabilities		 0.01 0.01 2.47 5.25 4.87 3.00
Commitments & Contingencies		 - - 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 36 39 22 17 19 25
Total Preferred & Common Equity		 36 39 22 17 19 25
Total Common Equity		 36 39 22 17 19 25
Common Stock		 143 150 188 198 200 218
Retained Earnings		 - - -162 -178 -178 -192
Accumulated Other Comprehensive Income / (Loss)		 -116 -120 -3.06 -3.01 -2.85 -2.06

Quarterly Balance Sheets for Neuphoria Therapeutics

This table presents Neuphoria Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q2 2025 Q3 2025 Q3 2026
Period end date 9/30/2025 12/31/2025 3/31/2025 3/31/2026
Total Assets		 27 37 31 35
Total Current Assets		 14 23 17 22
Cash & Equivalents		 14 22 17 19
Restricted Cash		 0.08 0.08 - 0.00
Accounts Receivable		 0.00 1.11 0.02 1.61
Prepaid Expenses		 0.22 0.03 0.02 0.61
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 13 13 14 13
Goodwill		 8.67 8.74 8.45 8.84
Intangible Assets		 4.64 4.47 4.97 4.31
Other Noncurrent Operating Assets		 0.08 0.00 0.20 0.00
Total Liabilities & Shareholders' Equity		 27 37 31 35
Total Liabilities		 15 6.90 4.72 5.39
Total Current Liabilities		 5.12 2.59 1.55 1.51
Accounts Payable		 1.37 0.52 0.75 0.63
Accrued Expenses		 3.67 2.07 0.68 0.89
Other Current Liabilities		 0.09 0.00 0.12 0.00
Total Noncurrent Liabilities		 9.71 4.31 3.16 3.87
Capital Lease Obligations		 0.00 0.00 0.02 0.00
Noncurrent Deferred & Payable Income Tax Liabilities		 0.46 0.43 0.76 0.39
Other Noncurrent Operating Liabilities		 9.25 3.89 2.38 3.48
Commitments & Contingencies		 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 13 30 26 29
Total Preferred & Common Equity		 13 30 26 29
Total Common Equity		 13 30 26 29
Common Stock		 204 218 199 218
Retained Earnings		 -188 -186 -169 -187
Accumulated Other Comprehensive Income / (Loss)		 -2.80 -2.23 -3.91 -2.07

Annual Metrics And Ratios for Neuphoria Therapeutics

This table displays calculated financial ratios and metrics derived from Neuphoria Therapeutics' official financial filings.

Metric 2020 2021 2022 2023 2024 2025 2026
Period end date 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025 6/30/2026
DEI Shares Outstanding		 0.00 0.00 1,353,350,744.00 1,486,735,424.00 1,486,735,424.00 1,879,962.00 5,404,551.00
DEI Adjusted Shares Outstanding		 0.00 0.00 1,353,350,744.00 1,486,735,424.00 1,486,735,424.00 1,879,962.00 5,404,551.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -0.01 -0.02 -0.01 -0.20 -2.49
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% -86.60% 4,266.57% -100.00% 0.00% 0.00% -92.50%
EBITDA Growth		 0.00% -60.17% -126.62% -40.94% 29.00% 97.74% -3,879.36%
EBIT Growth		 0.00% -60.17% -126.62% -45.32% 28.13% 93.64% -1,319.29%
NOPAT Growth		 0.00% -12.90% -72.39% -17.38% 18.61% 93.69% -1,357.02%
Net Income Growth		 0.00% -32.75% -129.94% -42.31% 27.54% 97.61% -3,539.28%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 98.76% -1,230.43%
Operating Cash Flow Growth		 0.00% -109.85% -168.53% 3.76% -0.29% 100.53% -16,095.38%
Free Cash Flow Firm Growth		 0.00% 0.00% 48.82% -1.43% 37.60% 93.16% -2,187.34%
Invested Capital Growth		 0.00% 0.00% -9.59% -26.01% -50.73% -5.72% 0.44%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -0.08% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -105.46% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -117.94% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 1.76% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -106.34% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -88.15% 27.98%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -47.46% 0.00%
Profitability Metrics		 - - - - - - -
Gross Margin		 -6,935.46% -53,024.60% 100.00% 0.00% 0.00% 100.00% 100.00%
EBITDA Margin		 -12,915.31% -154,333.92% -8,009.78% 0.00% 0.00% -2.18% -1,157.74%
Operating Margin		 -29,821.10% -251,187.42% -9,917.01% 0.00% 0.00% -7.21% -1,401.09%
EBIT Margin		 -12,915.31% -154,333.92% -8,009.78% 0.00% 0.00% -6.42% -1,214.20%
Profit (Net Income) Margin		 -15,254.89% -151,078.09% -7,955.79% 0.00% 0.00% -2.36% -1,145.66%
Tax Burden Percent		 118.11% 97.89% 99.13% 99.35% 99.44% 44.11% 98.98%
Interest Burden Percent		 100.00% 100.00% 100.20% 97.90% 98.61% 83.42% 95.33%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -100.26% -90.78% 0.00% 0.00% -16.27% -243.76%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -110.66% -82.49% 0.00% 0.00% -19.42% -232.42%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 63.72% 50.74% 0.00% 0.00% 14.25% 182.06%
Return on Equity (ROE)		 0.00% -36.54% -40.04% -69.75% -78.44% -2.03% -61.70%
Cash Return on Invested Capital (CROIC)		 0.00% -300.26% -80.70% -99.09% -97.41% -10.38% -244.20%
Operating Return on Assets (OROA)		 0.00% -16.37% -35.23% 0.00% 0.00% -3.57% -49.76%
Return on Assets (ROA)		 0.00% -16.03% -35.00% 0.00% 0.00% -1.31% -46.95%
Return on Common Equity (ROCE)		 0.00% -36.54% -40.04% -69.75% -78.44% -2.03% -61.70%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -18.27% -38.23% -97.14% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -6.74 -7.60 -13 -15 -13 -0.79 -12
NOPAT Margin		 -20,874.77% -175,831.20% -6,941.91% 0.00% 0.00% -5.05% -980.76%
Net Nonoperating Expense Percent (NNEP)		 0.00% 10.40% -8.29% -32.01% -24.37% 3.14% -11.34%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -71.13% -4.16% -46.81%
Cost of Revenue to Revenue		 7,035.46% 53,124.60% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 7,866.40% 75,961.25% 2,705.08% 0.00% 0.00% 49.67% 633.58%
R&D to Revenue		 12,489.40% 100,098.20% 5,849.66% 0.00% 0.00% 57.54% 301.95%
Operating Expenses to Revenue		 22,885.64% 198,162.82% 10,017.01% 0.00% 0.00% 107.21% 1,501.09%
Earnings before Interest and Taxes (EBIT)		 -4.17 -6.67 -15 -22 -16 -1.00 -14
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -4.17 -6.67 -15 -21 -15 -0.34 -14
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 0.56 0.29 135.27 0.00 0.70 0.96
Price to Tangible Book Value (P/TBV)		 0.00 1.06 0.48 414.32 0.00 2.40 1.39
Price to Revenue (P/Rev)		 620.81 4,631.61 60.03 0.00 0.00 0.85 20.11
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 292.24 0.00 0.00 0.79
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 3.20
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 0.01 0.01 0.01 0.01 0.00 0.00
Long-Term Debt to Equity		 0.00 0.01 0.01 0.01 0.01 0.00 0.00
Financial Leverage		 0.00 -0.58 -0.62 -0.61 -0.62 -0.73 -0.78
Leverage Ratio		 0.00 1.14 1.14 1.20 1.42 1.54 1.31
Compound Leverage Factor		 0.00 1.14 1.15 1.18 1.40 1.29 1.25
Debt to Total Capital		 0.00% 1.44% 0.93% 1.08% 0.67% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 1.44% 0.93% 1.08% 0.67% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 98.56% 99.07% 98.92% 99.33% 100.00% 100.00%
Debt to EBITDA		 0.00 -0.08 -0.02 -0.01 -0.01 0.00 0.00
Net Debt to EBITDA		 0.00 3.13 1.51 0.56 0.83 0.00 0.00
Long-Term Debt to EBITDA		 0.00 -0.08 -0.02 -0.01 -0.01 0.00 0.00
Debt to NOPAT		 0.00 -0.07 -0.03 -0.02 -0.01 0.00 0.00
Net Debt to NOPAT		 0.00 2.75 1.74 0.77 1.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 -0.07 -0.03 -0.02 -0.01 0.00 0.00
Altman Z-Score		 0.00 2.49 0.78 262.58 0.00 -7.01 -6.65
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 0.00 13.10 12.46 4.87 3.45 3.56 27.85
Quick Ratio		 0.00 12.16 10.02 4.57 3.33 3.37 27.33
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -23 -12 -12 -7.38 -0.50 -12
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.56 0.04
Accounts Receivable Turnover		 0.00 0.03 1.94 0.00 0.00 225.44 2.85
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.70 38.73 0.00 0.00 6,568.50 0.00
Accounts Payable Turnover		 0.00 1.69 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 12,694.40 188.30 0.00 0.00 1.62 128.29
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 216.55 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 12,477.85 188.30 0.00 0.00 1.62 128.29
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 0.00 15 14 10 5.00 4.71 4.73
Invested Capital Turnover		 0.00 0.00 0.01 0.00 0.00 3.22 0.25
Increase / (Decrease) in Invested Capital		 0.00 15 -1.46 -3.57 -5.15 -0.29 0.02
Enterprise Value (EV)		 0.00 -0.86 -11 2,966 0.00 -0.94 3.75
Market Capitalization		 20 20 11 2,977 0.00 13 24
Book Value per Share		 $0.00 $22.05 $0.03 $0.02 $21.02 $10.11 $4.55
Tangible Book Value per Share		 $0.00 $11.70 $0.02 $0.01 $4.00 $2.96 $3.14
Total Capital		 0.00 36 40 22 18 19 25
Total Debt		 0.00 0.52 0.37 0.24 0.12 0.00 0.00
Total Long-Term Debt		 0.00 0.52 0.37 0.24 0.12 0.00 0.00
Net Debt		 0.00 -21 -23 -12 -12 -14 -20
Capital Expenditures (CapEx)		 -0.18 -0.03 -0.30 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 0.05 3.38 -1.52 -3.24 -3.47 0.45
Debt-free Net Working Capital (DFNWC)		 0.00 21 27 11 9.36 11 20
Net Working Capital (NWC)		 0.00 21 27 11 9.36 11 20
Net Nonoperating Expense (NNE)		 -1.81 -1.07 1.91 5.99 2.97 -0.42 1.94
Net Nonoperating Obligations (NNO)		 0.00 -21 -26 -12 -12 -14 -20
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.66 0.66 0.66 0.66
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 1,164.05% 1,787.82% 0.00% 0.00% -22.16% 38.04%
Debt-free Net Working Capital to Revenue		 0.00% 496,234.08% 14,060.02% 0.00% 0.00% 69.14% 1,729.92%
Net Working Capital to Revenue		 0.00% 496,234.08% 14,060.02% 0.00% 0.00% 69.14% 1,729.92%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($0.01) ($0.23) ($3.06)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 1.35B 1.49B 1.80B 1.62M 4.40M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 ($0.23) ($3.06)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 1.35B 1.49B 0.00 1.62M 4.40M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 1.35B 1.49B 0.00 0.00 5.41M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.74 -7.60 -13 -15 -13 -0.79 -6.87
Normalized NOPAT Margin		 -20,874.77% -175,831.20% -6,941.91% 0.00% 0.00% -5.05% -584.87%
Pre Tax Income Margin		 -12,915.31% -154,333.92% -8,025.92% 0.00% 0.00% -5.35% -1,157.51%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.68% -4.78% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Neuphoria Therapeutics

This table displays calculated financial ratios and metrics derived from Neuphoria Therapeutics' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q3 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2025 3/31/2025 6/30/2025 3/31/2026
DEI Shares Outstanding		 1,486,735,424.00 1,486,735,424.00 1,486,735,424.00 1,486,735,424.00 2,357,613.00 3,514,922,864.00 1,757,027.00 1,879,962.00 5,390,895.00
DEI Adjusted Shares Outstanding		 1,486,735,424.00 1,486,735,424.00 1,486,735,424.00 1,486,735,424.00 2,357,613.00 3,514,922,864.00 1,757,027.00 1,879,962.00 5,390,895.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 0.00 0.00 -4.20 0.00 6.41 -4.73 -0.09
Growth Metrics		 - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00%
EBITDA Growth		 0.00% 0.00% 0.00% 0.00% 85.12% 140.82% 527.91% -251.15% -106.41%
EBIT Growth		 0.00% 0.00% 0.00% 0.00% 82.60% 135.79% 496.83% -236.01% -106.50%
NOPAT Growth		 0.00% 0.00% 0.00% 0.00% 34.75% -29.84% 819.90% -6.52% -107.03%
Net Income Growth		 0.00% 0.00% 0.00% 0.00% 85.29% 140.93% 505.38% -230.61% -104.48%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 85.50% 331.45% 47.04% -101.37%
Operating Cash Flow Growth		 0.00% 0.00% 0.00% 0.00% -0.07% 14.88% 521.62% -19.07% 0.00%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -160.14%
Invested Capital Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -5.72% 11.27%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.09% 0.00%
EBITDA Q/Q Growth		 0.00% 17.47% 40.85% 2.46% 68.75% 326.43% 519.98% -180.04% 0.00%
EBIT Q/Q Growth		 0.00% 16.96% 39.40% 2.32% 64.60% 270.80% 571.98% -182.71% 0.00%
NOPAT Q/Q Growth		 0.00% 16.73% 47.42% -128.81% 34.87% -65.69% 391.54% -133.86% 0.00%
Net Income Q/Q Growth		 0.00% 16.78% 39.00% 3.28% 70.05% 331.63% 504.16% -178.88% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 46.70% -270.32% 94.08% -24.19% 950.65% -184.73% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 10.94% 16.48% 8.63% -47.24% 11.50% 315.87% -131.30% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -805.81% 126.68% -222.84% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -124.36% 711.71% 20.42% -47.46% 0.00%
Profitability Metrics		 - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 75.56% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 79.85% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 74.45% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 75.08% 0.00% 0.00%
Tax Burden Percent		 99.37% 99.24% 100.59% 98.75% 85.89% 101.90% 100.73% 97.09% 93.56%
Interest Burden Percent		 98.48% 98.82% 98.13% 98.98% 96.29% 110.07% 100.11% 99.06% 74.36%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% -1.90% -0.73% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 280.81% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 290.24% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -190.07% 0.00% 0.00%
Return on Equity (ROE)		 0.00% 0.00% 0.00% -78.44% -159.28% -45.48% 90.74% 0.00% 0.00%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -147.55% 0.00% 0.00% 0.00% -10.38% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 37.97% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 38.29% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% 0.00% 0.00% -78.44% -159.28% -45.48% 90.74% 0.00% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.83 -3.19 -1.68 -3.83 -2.50 -4.14 12 -4.08 -0.85
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 80.43% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% 0.00% 0.00% 9.19% 24.66% 53.95% -9.42% -35.84% 1.88%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -21.78% -19.96% -13.93% 46.37% -21.49% -2.88%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 9.38% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 10.77% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 20.15% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -5.59 -4.64 -2.81 -2.75 -0.97 1.66 11 -9.24 -0.73
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -5.43 -4.48 -2.65 -2.58 -0.81 1.83 11 -9.07 -0.73
Valuation Ratios		 - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.70 0.39 0.70 0.75
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 1.27 0.80 2.40 1.35
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.65 0.85 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.25
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 0.00 0.00 -0.71 -1.10 -0.75 -0.65 -0.73 -0.66
Leverage Ratio		 0.00 0.00 0.00 1.42 2.19 1.23 1.18 1.54 1.18
Compound Leverage Factor		 0.00 0.00 0.00 1.41 2.10 1.36 1.18 1.53 0.88
Debt to Total Capital		 0.00% 0.00% 0.00% 0.67% 0.00% 0.00% 0.07% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.67% 0.00% 0.00% 0.07% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 0.00% 0.00% 99.33% 100.00% 100.00% 99.93% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 -0.01 0.00 0.00 -0.01 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.83 0.00 0.00 5.74 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 -0.01 0.00 0.00 -0.01 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 -0.01 0.00 0.00 -0.01 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 1.00 0.00 0.00 8.51 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 -0.01 0.00 0.00 -0.01 0.00 0.00
Altman Z-Score		 0.00 0.00 0.00 0.00 0.00 -4.48 -4.12 -7.96 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - -
Current Ratio		 0.00 0.00 0.00 3.45 2.72 9.04 11.01 3.56 14.31
Quick Ratio		 0.00 0.00 0.00 3.33 2.66 9.00 11.00 3.37 13.91
Cash Flow Metrics		 - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 0.00 0.00 0.00 -1.28 -12 3.09 -3.80 -1.86
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.51 0.56 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 636.90 225.44 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 9,650.47 6,568.50 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.57 1.62 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.57 1.62 0.00
Capital & Investment Metrics		 - - - - - - - - -
Invested Capital		 0.00 0.00 0.00 5.00 -1.22 7.45 8.97 4.71 9.98
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 3.49 3.22 0.00
Increase / (Decrease) in Invested Capital		 0.00 0.00 0.00 0.00 -1.22 7.45 8.97 -0.29 1.01
Enterprise Value (EV)		 0.00 0.00 0.00 0.00 0.00 -1.39 -6.90 -0.94 2.50
Market Capitalization		 3,654 0.00 0.00 0.00 0.00 21 10 13 22
Book Value per Share		 $0.00 $0.00 $0.00 $21.02 $9.62 $5.52 $14.80 $10.11 $5.46
Tangible Book Value per Share		 $0.00 $0.00 $0.00 $4.00 ($0.62) $3.07 $7.16 $2.96 $3.02
Total Capital		 0.00 0.00 0.00 18 13 30 26 19 29
Total Debt		 0.00 0.00 0.00 0.12 0.00 0.00 0.02 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.12 0.00 0.00 0.02 0.00 0.00
Net Debt		 0.00 0.00 0.00 -12 -14 -22 -17 -14 -19
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 0.00 0.00 -3.24 -4.90 -1.45 -1.51 -3.47 0.70
Debt-free Net Working Capital (DFNWC)		 0.00 0.00 0.00 9.36 8.83 21 16 11 20
Net Working Capital (NWC)		 0.00 0.00 0.00 9.36 8.83 21 16 11 20
Net Nonoperating Expense (NNE)		 1.65 1.37 1.10 -1.15 -1.69 -6.00 0.80 4.80 -0.34
Net Nonoperating Obligations (NNO)		 0.00 0.00 0.00 -12 -14 -22 -17 -14 -19
Total Depreciation and Amortization (D&A)		 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -9.62% -22.16% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 99.20% 69.14% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 99.20% 69.14% 0.00%
Earnings Adjustments		 - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 ($10.48) ($0.62) $0.41 $6.55 ($5.55) ($0.09)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 832.23K 1.30M 4.54M 1.72M 1.62M 5.41M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($10.48) ($0.62) ($0.77) $6.55 ($5.55) ($0.09)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 832.23K 1.30M 4.54M 1.72M 1.62M 5.41M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 0.00 5.38M 5.39M 1.88M 0.00 5.40M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.83 -3.19 -1.68 -3.83 -2.50 -1.98 8.38 -4.08 -0.82
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 55.89% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 74.54% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Neuphoria Therapeutics’ financial statements show a company with substantial liquidity and lower liabilities, but one that remains dependent on financing and has not established consistent operating revenue. The supplied filings include restated and calculated periods, and the latest cash-flow period does not align perfectly with the latest reported income statement and balance sheet, so quarter-to-quarter comparisons should be interpreted cautiously.

  • Liquidity remains strong relative to current obligations. As of March 31, 2026, Neuphoria reported $19.4 million in cash and equivalents against $1.5 million of current liabilities, implying a current ratio of approximately 14.3.
  • Liabilities have declined meaningfully. Total liabilities fell from $14.8 million in the reported Q1 2025 balance sheet to $5.4 million in Q3 2026, reducing balance-sheet leverage and improving financial flexibility.
  • Operating cash flow improved in the latest cash-flow data. Net cash from operating activities increased to $1.2 million in Q4 2026, compared with an outflow of $3.6 million in Q4 2025 and outflows of approximately $3.0 million to $6.4 million in several earlier periods.
  • Reported losses narrowed substantially in the latest comparable income statement. The Q3 2026 net loss was $505,000, versus an $8.9 million loss in Q4 2025. Operating expenses also declined to $1.2 million from $5.8 million over those periods.
  • Equity provides a sizable capital base. Total common equity was $29.4 million as of March 31, 2026, compared with $12.5 million in Q1 2025, although part of the increase reflects equity issuance rather than internally generated profits.
  • Cash levels have been volatile. Cash increased from $13.6 million in Q1 2025 to $22.2 million in Q2 2025, then declined to $17.0 million in Q3 2025 before recovering to $19.4 million in Q3 2026.
  • Noncurrent assets are concentrated in goodwill and intangible assets. These assets totaled approximately $13.2 million, or nearly 38% of total assets, in Q3 2026. Their value may depend on the performance of acquired businesses or intellectual property.
  • Revenue generation is inconsistent. Revenue was reported at $15.0 million in Q3 2025, $662,715 in Q2 2025, and zero in both Q1 2025 and Q3 2026. The lack of recurring revenue makes it difficult to assess the company’s underlying operating trajectory.
  • Neuphoria continues to report net losses. The company posted losses in most supplied periods, including a $4.9 million net loss in the latest Q4 2026 cash-flow data. Retained earnings remained deeply negative at approximately $186.9 million.
  • Shareholder dilution is a significant risk. Weighted-average shares increased from 1.6 million in Q4 2025 to 5.4 million in Q3 2026. The company has repeatedly used equity issuance to fund operations, including $14.7 million in Q2 2025 and $704,675 in Q4 2025.

Overall, Neuphoria’s balance sheet is supported by cash and relatively low liabilities, while recent operating expenses and cash usage appear to have improved. However, the company’s inconsistent revenue, continuing losses, reliance on equity financing and sharp increase in share count remain important risks for investors. The latest cash-flow improvement should be viewed as encouraging but not yet evidence of a durable shift toward self-funded operations.

09/24/26 06:56 AM ETAI Generated. May Contain Errors.

Neuphoria Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Neuphoria Therapeutics' financial year ends in June. Their financial year 2026 ended on June 30, 2026.

Neuphoria Therapeutics' net income appears to be on an upward trend, with a most recent value of -$13.45 million in 2026, rising from -$4.92 million in 2020. The previous period was -$369.63 thousand in 2025. See Neuphoria Therapeutics' forecast for analyst expectations on what's next for the company.

Neuphoria Therapeutics' total operating income in 2026 was -$16.45 million, based on the following breakdown:
  • Total Gross Profit: $1.17 million
  • Total Operating Expenses: $17.63 million

Over the last 6 years, Neuphoria Therapeutics' total revenue changed from $32.27 thousand in 2020 to $1.17 million in 2026, a change of 3,538.9%.

Neuphoria Therapeutics' total liabilities were at $4.11 million at the end of 2026, a 57.1% decrease from 2025, and a 18.0% decrease since 2021.

In the past 5 years, Neuphoria Therapeutics' cash and equivalents has ranged from $12.10 million in 2023 to $23.18 million in 2022, and is currently $19.87 million as of their latest financial filing in 2026.

Over the last 6 years, Neuphoria Therapeutics' book value per share changed from 0.00 in 2020 to 4.55 in 2026, a change of 455.2%.


Related Companies

Financial statements for NASDAQ:NEUP last updated on 9/18/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
While SpaceX Gets the Spotlight, FJET Is Building What Comes Next!
Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starf...
Trading Wire | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
How to get a stake in Anthropic — before the IPO
Anthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...
Weiss Ratings | Sponsoredtc pixel
If you keep cash in a U.S. bank account… read this NOW
Since 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...
Banyan Hill Publishing | Sponsoredtc pixel
They're shrinking your dollars every single month
Since 2020, the dollar has lost roughly a quarter of its buying power. A $500,000 nest egg today buys about wh...
American Alternative | Sponsoredtc pixel
Why I believe the AI market will split in Q4
Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...
The Oxford Club | Sponsoredtc pixel
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel